Alternative to Meds Editorial Team
Medically Reviewed by Dr John Motl MD
Don’t stop Spravato or your antidepressant on your own. If you have thoughts of suicide, call or text 988 now.
- What it is
- Spravato (esketamine), a nasal spray related to the anesthetic ketamine
- Approved for
- Treatment-resistant depression in adults, and depressive symptoms in adults with major depression and acute suicidal thoughts or behavior
- Where it’s given
- Only in a certified healthcare setting, under the Spravato REMS safety program
- Monitoring
- At least 2 hours after every dose; no driving until the next day after a restful sleep
- Boxed warning
- Sedation, dissociation, breathing problems, abuse and misuse, and suicidal thoughts in young people
- Controlled substance
- Schedule III
- Ketamine for depression
- Not FDA-approved for any psychiatric condition; given off-label
- At ATMC
- We don’t prescribe Spravato or ketamine. We help people with depression and supervised antidepressant tapering.
Table of contents (13)
- What is Spravato (esketamine)?
- Esketamine vs. ketamine: what’s the difference?
- How well does Spravato work?
- The Spravato REMS: why it’s only given in a clinic
- Spravato side effects and boxed warning
- Can you get addicted to Spravato or ketamine?
- Spravato and pregnancy
- Considering Spravato? Questions to ask
- Want to stop Spravato?
- When to get help right away
- How ATMC can help with depression
- Spravato and esketamine FAQs
- Sources
What is Spravato (esketamine)?
Spravato (esketamine) is a prescription nasal spray for depression that hasn’t improved with other treatments. It is approved for adults with treatment-resistant depression, and for depressive symptoms in adults with major depression who have acute suicidal thoughts or behavior, taken alongside an oral antidepressant.1
The FDA first approved Spravato on March 5, 2019.2 The suicidal-thoughts indication followed in 2020, and in January 2025 the FDA approved it for treatment-resistant depression on its own, without a daily oral antidepressant.1,3,4 “Treatment-resistant” generally means depression that has not responded well to at least two antidepressants.1
Spravato works differently from common antidepressants. It blocks NMDA receptors, part of the brain’s glutamate system, rather than acting mainly on serotonin.1 For some people it helps quickly, but it comes with real risks and strict rules about how it is given.
Want medical support while you taper? Learn how our residential medication tapering program in Sedona works, or call (888) 907-7075.
Esketamine vs. ketamine: what’s the difference?
Short answer: esketamine is one half of the ketamine molecule. Ketamine is a mix of two mirror-image forms, and esketamine is the “S” form.1 Spravato is FDA-approved for depression. Ketamine is approved only as an anesthetic.5,12
| Spravato (esketamine) | Ketamine for depression | |
|---|---|---|
| FDA status | Approved for treatment-resistant depression and for major depression with acute suicidal thoughts1 | Approved as an anesthetic; not approved for any psychiatric condition5,6,12 |
| How it’s given | Nasal spray, self-given under direct observation in a certified clinic1 | Off-label in clinics, by injection, nasal spray, or by mouth; also sold as compounded oral or nasal products5,6 |
| Safety program | Spravato REMS, with at least 2 hours of monitoring per dose1 | No REMS for compounded products6 |
| Take-home use | Not allowed1 | The FDA has warned about at-home use of compounded ketamine6 |
| Controlled substance | Schedule III1 | Schedule III; also made and sold illegally as a recreational drug5,12 |
FDA warning on at-home ketamine. In October 2023, the FDA warned patients and clinicians about compounded ketamine, including oral forms sold through telehealth for psychiatric conditions. It noted that compounded ketamine is not FDA-approved, that home use means no one is monitoring sedation, dissociation, blood pressure, or heart rate, and that it described a patient who had breathing problems after taking compounded oral ketamine at home.6
How well does Spravato work?
Short answer: in clinical trials, Spravato improved depression scores more than placebo, and for some people the effect showed up within about 24 hours.1 It does not help everyone, and the effect needs ongoing treatment to last.
- Speed. In the trials, much of the difference from placebo appeared at about 24 hours.1
- Staying well. In a relapse-prevention trial, people who had improved and kept taking esketamine with their antidepressant relapsed less often than those switched to placebo spray. Among those in stable remission, 27% relapsed on esketamine versus 45% on placebo.7
- Suicidal thoughts. The label states that Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospital care when that is needed.1
Depression has many contributors, including sleep, stress, trauma, substance use, and physical health. Spravato can be one part of a plan, not the whole plan.
The Spravato REMS: why it’s only given in a clinic
Short answer: because of the risks of sedation, dissociation, breathing problems, and misuse, Spravato is only available through a restricted FDA safety program called a REMS (Risk Evaluation and Mitigation Strategy).1
Under the Spravato REMS:1,8
- Certified settings only. Spravato is dispensed and given only in healthcare settings certified in the REMS. Pharmacies must be certified too, and can ship only to certified settings.
- No take-home doses. You use the spray yourself, under the direct observation of a healthcare provider.
- Two hours of monitoring. A provider watches you for at least 2 hours after every dose, then checks that you are stable before you leave.
- Enrollment. Patients treated in outpatient settings, such as clinics and medical offices, must be enrolled in the program.
Plan your ride home. The label says not to drive or operate machinery until the next day, after a restful sleep.1 Blood pressure is checked before each dose and again about 40 minutes after.1
Looking for another way forward with depression? Talk to our team about residential care and supervised antidepressant tapering.
Call (888) 907-7075Free, confidential consultation
Spravato side effects and boxed warning
Short answer: the most common side effects are dissociation (feeling detached or unreal), dizziness, nausea, sedation, and a spinning feeling. These effects mostly happen on treatment days. Nausea and vomiting, for example, usually passed the same day in trials.1
The boxed warning, the FDA’s strongest, covers five risks:1
- Sedation. In trials, 48% to 61% of people became sedated, and a small number lost consciousness.
- Dissociation. 61% to 84% had dissociative or perceptual changes, such as distorted time or space, or feeling outside their body.
- Respiratory depression. Slowed breathing has been reported since approval.
- Abuse and misuse. Spravato can be misused. Prescribers are told to weigh this risk carefully, especially with a history of substance use.
- Suicidal thoughts and behaviors. Like all antidepressants, it carries a warning about suicidal thoughts in children and young adults. Spravato is not approved for children.
Common side effects in treatment-resistant depression trials included dissociation, dizziness, nausea, sedation, vertigo, numbness, anxiety, lethargy, higher blood pressure, vomiting, feeling drunk, and headache.1
Other warnings on the label:1
- Higher blood pressure, peaking about 40 minutes after a dose and lasting about 4 hours. Spravato should not be used by people with certain blood vessel conditions, such as an aneurysm, or a history of bleeding in the brain.
- Thinking and reaction time can be impaired after a dose.
- Bladder symptoms. Long-term misuse of ketamine has caused serious bladder inflammation. Trials of Spravato found more urinary symptoms than placebo, though no cases of that bladder condition.
Can you get addicted to Spravato or ketamine?
Short answer: it is possible. Esketamine is a Schedule III controlled substance with a boxed warning for abuse and misuse, and physical dependence and tolerance have been reported with long-term ketamine use.1
What the label and research say:
- Abuse potential. People with a history of drug or alcohol problems may be at greater risk. Effects can include euphoria, floating, detachment, and hallucinations.1
- Withdrawal. No withdrawal symptoms were captured in the 4 weeks after esketamine was stopped in trials. Withdrawal has been reported after frequent, large doses of ketamine over long periods, with craving, fatigue, poor appetite, and anxiety.1
- Tolerance. Tolerance has been reported with long-term ketamine use and would be expected with esketamine too.1
- Brain changes. Lab research shows ketamine can cause brain changes typical of drugs with addictive potential, and researchers are still working out how addictive it is.5
The REMS and in-clinic dosing are designed to reduce misuse. Off-label and at-home ketamine products do not have the same safeguards.6 If you are worried about your ketamine use, our addiction treatment program and dual diagnosis care can help.
Spravato and pregnancy
Spravato is not recommended during pregnancy. Animal research with ketamine suggests it may harm a developing baby, and the label advises people who could become pregnant to plan and prevent pregnancy during treatment.1 If you become pregnant while taking it, tell your prescriber. Untreated depression in pregnancy also carries risks, so any change should be made with your care team.1
Considering Spravato? Questions to ask
Short answer: make sure you understand the time commitment, the monitoring, and the risks for you personally.
- Have my sleep, physical health, labs, and other medications been looked at as possible contributors to my depression?
- Do I have high blood pressure, heart or blood vessel problems, or a history of substance use that changes the risk?1
- How often would I need treatment, and for how long?
- How will I get home after each session?
- What happens if it doesn’t help, or if I want to stop later?
- Is the clinic certified in the Spravato REMS?8
Want to stop Spravato?
Short answer: talk with your prescriber first. Stopping is not usually linked with withdrawal in trials, but depression can come back.1,7
In the relapse-prevention trial, people who stopped esketamine after doing well were more likely to relapse than those who continued.7 That doesn’t mean you can never stop. It means stopping works best as a planned decision with follow-up, not a sudden one.
Things to plan with your prescriber:
- The timing, and whether sessions are spaced out first
- What happens with your oral antidepressant, if you take one
- Which early signs of relapse to watch for, such as changes in sleep, energy, or hopelessness
- What support you have in place: therapy, sleep, exercise, and people you trust
If you also want to reduce or come off your oral antidepressant, that needs its own slow, supervised plan. Stopping an antidepressant suddenly can cause withdrawal symptoms.9 Read about antidepressant withdrawal and antidepressant tapering.
When to get help right away
- Call or text 988 for the Suicide and Crisis Lifeline if you have thoughts of suicide or self-harm. It is free and open 24/7.10
- Call 911 if someone is hard to wake or breathing slowly, or has chest pain, shortness of breath, a sudden severe headache, vision changes, or a seizure.1
- Call the SAMHSA National Helpline at 1-800-662-4357 for confidential treatment referrals for mental health or substance use, at no cost, 24/7.11
Suicidal thoughts often come from unbearable emotional pain. Being heard by someone who asks about that pain, without judgment, can help. You don’t have to wait for a crisis to reach out.
How ATMC can help with depression
Alternative to Meds Center is a residential treatment center in Sedona, Arizona. We don’t prescribe or give Spravato or ketamine. Our work is helping people with depression look at the whole picture, and helping those who want to reduce psychiatric medications do it slowly and safely.
Medication can have a real role in treating depression. Physical health matters too. Every resident gets lab testing and a medical assessment, and care includes nutrition, counseling, neurotransmitter support, and peer support. Each week you meet with your therapist, the medical director and nursing team, a naturopathic doctor, and your care manager. No medication decisions are made without you.
Our Medical Director describes how the team runs a taper:
“Our medical and nursing teams collaborate closely to monitor each client’s tapering plan, assess progress, and make adjustments as clinically indicated. The team regularly evaluates symptoms, sleep patterns, mood, and overall well-being to support a safe and individualized process.”
Kimberli Galloway, PMHNP-BC, Medical Director
Learn more about supervised medication tapering, one client’s depression recovery story, and blood tests for depression and anxiety.
Talk to our admissions team. Ask about residential care for depression, antidepressant tapering, what a stay looks like, and insurance. Family members are welcome to call.
Call (888) 907-7075Free, confidential consultation
Spravato and esketamine FAQs
Sources:
1. Janssen Pharmaceuticals. SPRAVATO (esketamine) nasal spray, CIII, prescribing information. DailyMed, National Library of Medicine. Revised September 2026. [cited 2026 Oct 20]
2. U.S. Food and Drug Administration. NDA 211243 approval letter, Spravato (esketamine) nasal spray. March 5, 2019. [cited 2026 Oct 20]
3. U.S. Food and Drug Administration. NDA 211243/S-004 supplement approval letter: depressive symptoms in adults with MDD with acute suicidal ideation or behavior. 2020. [cited 2026 Oct 20]
4. Healio Psychiatry. FDA approves Spravato as monotherapy for adults with major depressive disorder. January 22, 2025. [cited 2026 Oct 20]
5. National Institute on Drug Abuse. Ketamine. [cited 2026 Oct 20]
6. U.S. Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. October 10, 2023 (archived copy linked from FDA’s Compounding Risk Alerts page). [cited 2026 Oct 20]
7. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. doi:10.1001/jamapsychiatry.2019.1189. PMID: 31166571. [cited 2026 Oct 20]
8. Spravato REMS. SPRAVATO Risk Evaluation and Mitigation Strategy. [cited 2026 Oct 20]
9. National Institute of Mental Health. Mental Health Medications. [cited 2026 Oct 20]
10. 988 Suicide and Crisis Lifeline. 988lifeline.org. [cited 2026 Oct 20]
11. Substance Abuse and Mental Health Services Administration. SAMHSA’s National Helpline. [cited 2026 Oct 20]
12. Par Health USA. KETALAR (ketamine hydrochloride) injection, prescribing information. DailyMed, National Library of Medicine. [cited 2026 Oct 20]
Originally Published June 19, 2024 by Diane Ridaeus

Dr. John Motl, M.D.
Dr. Motl is currently certified by the American Board of Psychiatry and Neurology in Psychiatry, and Board eligible in Neurology and licensed in the state of Arizona. He holds a Bachelor of Science degree with a major in biology and minors in chemistry and philosophy. He graduated from Creighton University School of Medicine with a Doctor of Medicine. Dr. Motl has studied Medical Acupuncture at the Colorado School of Traditional Chinese Medicine and at U.C.L.A.
Social Profile: LinkedIn

Diane is an avid supporter and researcher of natural mental health strategies. Diane received her medical writing and science communication certification through Stanford University and has published over 3 million words on the topics of holistic health, addiction, recovery, and alternative medicine. She has proudly worked with the Alternative to Meds Center since its inception and is grateful for the opportunity to help the founding members develop this world-class center that has helped so many thousands regain natural mental health.